Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
sosei.com

See what CB Insights has to offer

About Sosei Group

Provider of biopharmaceutical research, development, and commercialization in Japan. The company's lead product candidate is being developed to treat chronic obstructive pulmonary disease (COPD). It is also developing drugs for emergency contraception and neuropathic pain.

Sosei Group Headquarter Location

Kojimachi Tsuruya Hachiman Building 5F 2-4 Kojimachi, Chiyodaku-ku

Tokyo, 102-0083,

Japan

81 3 5210 3290

Latest Sosei Group News

Sosei Heptares And InveniAI Enter A Multi-target AI-powered And GPCR-focused Drug Discovery Collaboration

Jul 6, 2021

Sosei Heptares And InveniAI Enter A Multi-target AI-powered And GPCR-focused Drug Discovery Collaboration Creating transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform, AlphaMeld®, with Sosei Heptares' GPCR Structure-based Drug Design and early development capabilities Author: Jul 6, 2021 3:00 AM EDT TOKYO and CAMBRIDGE, England, July 6, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565), the world leader in GPCR-focused structure-based drug design and development, and InveniAI ® LLC ("InveniAI," Guilford, CT, USA), a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, announced today the initiation of a new R&D collaboration. The objective of the collaboration is to identify new therapeutic product concepts for immune diseases where an AI and ML based approach can be applied to generate compelling evidence for the role of G-protein coupled receptors (GPCRs) in relevant immunomodulatory pathways; the goal being to use these targets as a basis for SBDD to generate novel compounds that could improve responses to existing immunotherapies. The collaboration will combine InveniAI's AI-powered platform for target discovery with Sosei Heptares' world-leading GPCR structure-based drug design and early development capabilities generate and advance transformative therapeutics across disease indications that remain with high unmet medical needs. Dr. Miles Congreve, Ph.D., Chief Scientific Officer, Sosei Heptares, said:"We are excited to work together with InveniAI and look forward to integrating our unique capabilities to seek and identify new links between undrugged GPCR targets and compelling disease indications. This collaboration has the potential to further extend our GPCR-focused drug discovery and early development capabilities. GPCRs represent an important class of pharmaceutical targets, and it is estimated that about 30% of known drugs have their mode of action through a relatively small number of GPCRs. This leaves a significant number of remaining GPCR targets that could be attractive for therapeutic intervention. InveniAI's AlphaMeld® platform will deconvolute the biology of disease and industrialize target discovery by rapidly unravelling connections between GPCR targets and diseases with high unmet need." InveniAI's Chief Business Officer, Aman Kant, added, "We are delighted to collaborate with Sosei Heptares, an industry leader in GPCR-based therapeutic modality. We have consistently demonstrated our AI capabilities in generating clinic-ready programs across various therapeutic modalities, including biologics, small molecules, and nucleotide-based therapies. This collaboration will leverage InveniAI's AI-based high-throughput discovery pipeline with Sosei Heptares' complementary chemistry approach to deliver drug candidates efficiently, at a scale, and with an enhanced probability of clinical success. We continue to be excited about AlphaMeld's potential, as numerous candidates have now progressed to various stages in clinical development as far as NDA submission." About Sosei Heptares We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases. We have established partnerships with some of the world's leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), Novartis, Pfizer and Takeda. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK. "Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies. For more information, please visit https://soseiheptares.com/ LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco About InveniAI ® InveniAI ® LLC, based in Guilford, Conn., is a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development by identifying and accelerating transformative therapies for diseases with unmet medical needs. The company leverages, AlphaMeld ®, an AI- and ML-powered platform, to harness petabytes of disparate data sets to recognize and unlock value for drug discovery and development. Numerous industry collaborations in Big Pharma, Specialty Pharma, Biotech, and Consumer Healthcare showcase the value of leveraging our technology to meld human experience and expertise with the power of machines to augment R&D decision-making across all major therapeutic areas. The company leverages AlphaMeld ® to augment and accelerate drug discovery programs for our industry partners and an internal portfolio of programs addressing highly debilitating, functional, chronic inflammatory, and autoimmune gastrointestinal (GI) disorders driven by dysregulation of the gut-brain axis. For more information, please visit: https://www.inveniai.com/ Enquiries: Hironoshin NomuraSVP Investor Relations and Corporate Strategy +81 (0)3 6679 2178 Hironoshin.Nomura@SoseiHeptares.com Shinichiro NishishitaVP Investor RelationsHead of Regulatory Disclosures +81 (0)3 5210 3399  IR@SoseiHeptares.com Citigate Dewe Rogerson (for Japanese Media) Yas Fukuda+81 (0)3 4360 9234 Yas.Fukuda@citigatedewerogerson.com MEDiSTRAVA Consulting (for International Media) Mark Swallow, David Dible+44 (0)20 7638 9571 SoseiHeptares@medistrava.com InveniAI LLC Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. View original content: https://www.prnewswire.com/news-releases/sosei-heptares-and-inveniai-enter-a-multi-target-ai-powered-and-gpcr-focused-drug-discovery-collaboration-301325815.html

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.